Jochen Huber
9Patents
4h-index
27Co-inventors
57Inventor score
Filing activity: Jul 11, 2002 → Mar 20, 2023
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7169612B2 | Use of EDG2 receptor in an animal model of heart failure | Chemistry; Metallurgy | 34 | Expired |
| US8772469B2 | Synthetic double-stranded oligonucleotides for specific inhibition of gene expression | Chemistry; Metallurgy | 25 | Expired |
| US7279286B2 | High-throughput-assay with high sensitivity for measuring of the activity of β-adrenergic receptor kinase and for determining the impact of test substances on such activity | Chemistry; Metallurgy | 18 | Expired |
| US7635769B2 | Oligoribonucleotide derivatives for specific inhibition of gene expression | Chemistry; Metallurgy | 9 | Expired |
| US11690848B2 | Alkoxy pyrazoles as soluble guanylate cyclase activators | Human Necessities | 1 | Active |
| US7910602B2 | Pyrazolopyridine derivatives as inhibitors of β-Adrenergic receptor kinase 1 | Human Necessities | 0 | Active |
| US6930103B2 | Use of vasopeptidase inhibitors in the treatment of metabolic diseases, nephropathy and advanced glycation end-product associated diseases | Human Necessities | 0 | Expired |
| US7514423B2 | Use of vasopeptidase inhibitors in the treatment of metabolic diseases, nephropathy and advanced glycation end-product associated diseases | Human Necessities | 0 | Active |
| US12226411B2 | Soluble guanylate cyclase activators for treating portal hypertension | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.